Claire Mazumdar - Oct 16, 2025 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
Chief Executive Officer, Director
Signature
/s/ Lara Meisner, Attorney-in-Fact
Stock symbol
BCAX
Transactions as of
Oct 16, 2025
Transactions value $
-$362,415
Form type
4
Date filed
10/20/2025, 04:11 PM
Previous filing
Oct 15, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mazumdar Claire Chief Executive Officer, Director BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON /s/ Lara Meisner, Attorney-in-Fact 2025-10-20 0002034671

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCAX Common Stock Options Exercise $91.3K +24.1K +7.78% $3.79 334K Oct 16, 2025 Direct F1
transaction BCAX Common Stock Sale -$454K -24.1K -7.22% $18.83 310K Oct 16, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCAX Stock Option (Right to Buy) Options Exercise $0 -24.1K -8% $0.00 277K Oct 16, 2025 Common Stock 24.1K $3.79 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3 The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.